AU2016370626B2 - Compositions comprising 15-HEPE and methods of using the same - Google Patents

Compositions comprising 15-HEPE and methods of using the same Download PDF

Info

Publication number
AU2016370626B2
AU2016370626B2 AU2016370626A AU2016370626A AU2016370626B2 AU 2016370626 B2 AU2016370626 B2 AU 2016370626B2 AU 2016370626 A AU2016370626 A AU 2016370626A AU 2016370626 A AU2016370626 A AU 2016370626A AU 2016370626 B2 AU2016370626 B2 AU 2016370626B2
Authority
AU
Australia
Prior art keywords
hepe
subject
pharmaceutically acceptable
composition
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016370626A
Other languages
English (en)
Other versions
AU2016370626A1 (en
Inventor
John Climax
David Coughlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afimmune Ltd
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of AU2016370626A1 publication Critical patent/AU2016370626A1/en
Application granted granted Critical
Publication of AU2016370626B2 publication Critical patent/AU2016370626B2/en
Priority to AU2020267224A priority Critical patent/AU2020267224B2/en
Priority to AU2022291628A priority patent/AU2022291628B2/en
Priority to AU2025201593A priority patent/AU2025201593A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2016370626A 2015-12-18 2016-12-19 Compositions comprising 15-HEPE and methods of using the same Active AU2016370626B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020267224A AU2020267224B2 (en) 2015-12-18 2020-11-11 Compositions comprising 15-HEPE and methods of using the same
AU2022291628A AU2022291628B2 (en) 2015-12-18 2022-12-23 Compositions comprising 15-HEPE and methods of using the same
AU2025201593A AU2025201593A1 (en) 2015-12-18 2025-03-05 Compositions comprising 15-HEPE and methods of using the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562269280P 2015-12-18 2015-12-18
US62/269,280 2015-12-18
PCT/IB2016/001878 WO2017103671A1 (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020267224A Division AU2020267224B2 (en) 2015-12-18 2020-11-11 Compositions comprising 15-HEPE and methods of using the same

Publications (2)

Publication Number Publication Date
AU2016370626A1 AU2016370626A1 (en) 2018-08-02
AU2016370626B2 true AU2016370626B2 (en) 2020-08-20

Family

ID=57995240

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2016370626A Active AU2016370626B2 (en) 2015-12-18 2016-12-19 Compositions comprising 15-HEPE and methods of using the same
AU2020267224A Active AU2020267224B2 (en) 2015-12-18 2020-11-11 Compositions comprising 15-HEPE and methods of using the same
AU2022291628A Active AU2022291628B2 (en) 2015-12-18 2022-12-23 Compositions comprising 15-HEPE and methods of using the same
AU2025201593A Pending AU2025201593A1 (en) 2015-12-18 2025-03-05 Compositions comprising 15-HEPE and methods of using the same

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020267224A Active AU2020267224B2 (en) 2015-12-18 2020-11-11 Compositions comprising 15-HEPE and methods of using the same
AU2022291628A Active AU2022291628B2 (en) 2015-12-18 2022-12-23 Compositions comprising 15-HEPE and methods of using the same
AU2025201593A Pending AU2025201593A1 (en) 2015-12-18 2025-03-05 Compositions comprising 15-HEPE and methods of using the same

Country Status (18)

Country Link
US (5) US9855238B2 (OSRAM)
EP (2) EP3389647B1 (OSRAM)
JP (4) JP2018537513A (OSRAM)
KR (6) KR20220038818A (OSRAM)
CN (2) CN108697680A (OSRAM)
AR (1) AR107143A1 (OSRAM)
AU (4) AU2016370626B2 (OSRAM)
BR (1) BR122023026625A2 (OSRAM)
CA (2) CA3008774C (OSRAM)
ES (1) ES2948444T3 (OSRAM)
IL (3) IL318963A (OSRAM)
MX (2) MX394051B (OSRAM)
NZ (1) NZ744323A (OSRAM)
PH (1) PH12018501279A1 (OSRAM)
RU (2) RU2020137883A (OSRAM)
SG (1) SG11201805149XA (OSRAM)
WO (1) WO2017103671A1 (OSRAM)
ZA (2) ZA201804779B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
HK1250345A1 (zh) 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
EP3861995A1 (en) 2015-07-21 2021-08-11 Affimune Limited Compositions comprising 15-hepe for use in treating or preventing neurologic disease
BR122023026625A2 (pt) 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo
CN113116878A (zh) * 2020-01-10 2021-07-16 南京大学 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11622495B2 (en) 2021-06-01 2023-04-11 Gint Co., Ltd. Method of automatically combining farm vehicle and work machine and farm vehicle
CN113855659B (zh) * 2021-11-24 2022-12-23 中国人民解放军东部战区总医院 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
WO2014019919A1 (en) * 2012-07-30 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-ohepa and methods of using the same
EP2762143A1 (en) * 2013-01-30 2014-08-06 Dignity Sciences Limited Compositions comprising 15-OHEPA and methods of using the same
WO2015071766A1 (en) * 2013-11-15 2015-05-21 Dignity Sciences Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
WO2016090030A1 (en) * 2014-12-02 2016-06-09 Dignity Sciences Limited Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
WO2016113635A1 (en) * 2015-01-16 2016-07-21 Dignity Sciences Limited Compositions comprising 15-hepe and methods of using the same
WO2017013492A1 (en) * 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
BR9405620A (pt) 1993-10-01 1999-09-08 Scherer Corp R P Cápsula de gelatina contendo fragr‰ncia, e, processo para sua preparação
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
ATE344226T1 (de) 2000-02-16 2006-11-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
ES2238568T3 (es) 2001-05-30 2005-09-01 Laxdale Limited Uso del coenzima q (ubiquinona) y acido eicosapentaenoico (epa) para el tratamiento del linfoma no hodgkin y trastornos psiquiatricos o neurologicos.
JPWO2004048497A1 (ja) 2002-11-22 2006-03-30 日本水産株式会社 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
GB2409644B (en) 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
CN101043884A (zh) 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP5504405B2 (ja) * 2005-06-10 2014-05-28 国立大学法人山口大学 血管病予防に効果を有する食品組成物
ES2527438T3 (es) 2006-08-08 2015-01-26 Metabolon, Inc. Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2010229099A (ja) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2010134614A1 (ja) * 2009-05-22 2010-11-25 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
CA2856715A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
JP6399655B2 (ja) 2012-01-06 2018-10-03 オムセラ・ファーマシューティカルズ・インコーポレイテッド 遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
HK1204978A1 (zh) * 2012-03-30 2015-12-11 桑茨利奥&孔帕尼股份有限公司 ω-3脂肪酸酯组合物
DK2833740T3 (da) 2012-04-04 2017-01-02 Pronova Biopharma Norge As Sammensætninger omfattende omega-3-fedtsyrer og D-vitamin til acne vulgaris og/eller eksem og fremgangsmåder og anvendelser deraf
JP6370775B2 (ja) * 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
EP3023099B1 (en) * 2013-07-18 2020-09-30 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of -3 fatty acid
CA2935986A1 (en) * 2014-01-10 2015-07-16 Mehar Manku Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
HK1250345A1 (zh) * 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
BR122023026625A2 (pt) * 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
WO2014019919A1 (en) * 2012-07-30 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-ohepa and methods of using the same
EP2762143A1 (en) * 2013-01-30 2014-08-06 Dignity Sciences Limited Compositions comprising 15-OHEPA and methods of using the same
WO2015071766A1 (en) * 2013-11-15 2015-05-21 Dignity Sciences Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
WO2016090030A1 (en) * 2014-12-02 2016-06-09 Dignity Sciences Limited Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
WO2016113635A1 (en) * 2015-01-16 2016-07-21 Dignity Sciences Limited Compositions comprising 15-hepe and methods of using the same
WO2017013492A1 (en) * 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease

Also Published As

Publication number Publication date
KR20250130433A (ko) 2025-09-01
RU2737089C2 (ru) 2020-11-24
KR20180094516A (ko) 2018-08-23
KR20230047501A (ko) 2023-04-07
ZA201804779B (en) 2019-09-25
PH12018501279A1 (en) 2019-01-28
EP4218736A2 (en) 2023-08-02
EP3389647A1 (en) 2018-10-24
RU2018126361A3 (OSRAM) 2020-01-22
CA3008774A1 (en) 2017-06-22
NZ783466A (en) 2025-05-30
US10231945B2 (en) 2019-03-19
KR20200055154A (ko) 2020-05-20
AU2020267224A1 (en) 2020-12-10
JP2018537513A (ja) 2018-12-20
IL318963A (en) 2025-04-01
CN113230244A (zh) 2021-08-10
BR112018012313A2 (pt) 2018-12-04
US20180104207A1 (en) 2018-04-19
KR20220038818A (ko) 2022-03-29
AU2025201593A1 (en) 2025-03-20
MX379262B (es) 2025-03-10
RU2018126361A (ru) 2020-01-22
EP4218736A3 (en) 2023-10-18
ES2948444T3 (es) 2023-09-12
CA3008774C (en) 2021-10-12
US12274685B2 (en) 2025-04-15
NZ766360A (en) 2025-05-30
NZ744323A (en) 2020-08-28
KR20240052856A (ko) 2024-04-23
MX2021000773A (es) 2022-07-19
AU2020267224B2 (en) 2022-09-29
MX2018007390A (es) 2018-11-09
JP2020063259A (ja) 2020-04-23
JP2023153863A (ja) 2023-10-18
IL294736A (en) 2022-09-01
JP2021178840A (ja) 2021-11-18
MX394051B (es) 2025-03-24
AU2022291628A1 (en) 2023-02-02
US20230106655A1 (en) 2023-04-06
CN108697680A (zh) 2018-10-23
ZA202104969B (en) 2023-01-25
AU2016370626A1 (en) 2018-08-02
IL259846A (en) 2018-07-31
AU2022291628B2 (en) 2025-04-03
EP3389647B1 (en) 2023-04-05
WO2017103671A1 (en) 2017-06-22
SG11201805149XA (en) 2018-07-30
CA3129008A1 (en) 2017-06-22
US20190224154A1 (en) 2019-07-25
AR107143A1 (es) 2018-03-28
BR122023026625A2 (pt) 2024-01-16
US9855238B2 (en) 2018-01-02
RU2020137883A (ru) 2020-12-03
US20170172965A1 (en) 2017-06-22
US20250281442A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
AU2022291628B2 (en) Compositions comprising 15-HEPE and methods of using the same
US20210228524A1 (en) Compositions comprising 15-ohepa and methods of using the same
US20190216761A1 (en) Compositions comprising 15-hepe and methods of using the same
BR112018012313B1 (pt) Uso de ácido 15-hidroxieicosapentaenoico ou de um derivado farmaceuticamente aceitável do mesmo para inibir ou aliviar uma doença selecionada dentre artrite, doença de huntington, sensibilidade à insulina comprometida, psoríase, câncer de pele, diferenciação de adipócitos, dor e obesidade

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)